Introduction/Background*The Study 111 established LenPem as a treatment option in patients with advanced endometrial cancer following prior systemic therapy. LenPem has a higher objective response rate (ORR) and progression-free survival (PFS) with a different toxicity profile. The aim of this study was to gather data regarding the efficacy and safety of LenPem when used in the real-world treatment of EC.. This is the first study to examine LenPem using (?) in EC patients treated in Russia in real practice.

Methodology Retrospective chart review identified 34 patients administred LenPem for treatment of recurrent EC in Russia from March 2020 to March 2021. Demographic and clinical data were analized.

Result(s)*Thirty-four patients (median age 66,9 years, range 57–83 years; 20,6% of patients with serous carcinoma, 82,4% ECOG ≤1, 64,7% pts with ≥2 relapses, 38,2% patients with ≥3 prior platinum-based chemotherapeutic regimens) received 1-14 cycles (median 3). In 23 patients who were examined for efficacy, the response rate (RR) was 26.2% and stabizilazion observed in 69.6% cases. Incidence of grade =>3 adverse events was similar to that in prior studies (overall 97%). The most common side effects in this study and study 111 were fatigue (64,7% and 51,1%, respectively), hypertension (47,1% and 61,7%, respectively), diarrhea (8,8% and 53,2% respectively) and stomatitis (8,8% and 35,1% respectively). Overall, 29,4% pts required dose reduction due to toxicity and in 11,8% cases required discontinuation due to disease progression.

Conclusion*Outcomes of advanced EC patients treated in Russia with LenPem following prior systemic therapy are comparable to those demonstrated in the Study 111. LEN appears to be effective and safe in real world practice in EC.